In this study, a novel class of multifunctional responsive nanoparticles is designed and fabricated as drug nanocarriers for synergetic chemo–photothermal therapy of tumors. The proposed nanoparticles are composed of a thermo-/pH-responsive poly­(N-isopropylacrylamide-co-acrylic acid) (PNA) nanogel core, a polydopamine (PDA) layer for photothermal conversion, and an outer folic acid (FA) layer as a targeting agent for the folate receptors on tumor cells. The fabricated nanoparticles show good biocompatibility and outstanding photothermal conversion efficiency. The proposed nanoparticles loaded with doxorubicin (DOX) drug molecules are stable under physiological conditions with low leakage of drugs, while rapidly release drugs in environments with low pH conditions and at high temperature. The experimental results show that the drug release process is mainly governed by Fickian diffusion. In vitro cell experimental results demonstrate that the PNA–DOX@PDA–FA nanoparticles can be phagocytized by 4T1 tumor cells and release drugs in tumor cell acidic environments, and confirm that the combined chemo and photothermal therapeutic efficacy of PNA–DOX@PDA–FA nanoparticles is higher than the photothermal therapeutic efficacy or the chemotherapeutic efficacy alone. The proposed multifunctional responsive nanoparticles in this study provide a novel class of drug nanocarriers as a promising tool for synergetic chemo–photothermal therapy of tumors.

Facile fabrication of novel functional membranes with excellent dual thermo- and pH-responsive characteristics has been achieved by simply designing dual-layer composite membranes. pH-Responsive poly(styrene)-block-poly(4-vinylpyridine) (PS-b-P4VP) block copolymers and polystyrene blended with thermoresponsive poly(N-isopropylacrylamide) (PNIPAM) nanogels are respectively used to construct the top layer and bottom layer of composite membranes. The stretching/coiling conformation changes of the P4VP chains around the pK (∼3.5-4.5) provide the composite membranes with extraordinary pH-responsive characteristics, and the volume phase transitions of PNIPAM nanogels at the pore/matrix interfaces in the bottom layer around the volume phase transition temperature (VPTT, ∼33 °C) provide the composite membranes with great thermoresponsive characteristics. The microstructures, permeability performances, and dual stimuli-responsive characteristics can be well tuned by adjusting the content of PNIPAM nanogels and the thickness of the PS-b-P4VP top layer. The water fluxes of the composite membranes can be changed in order of magnitude by changing the environment temperature and pH, and the dual thermo- and pH-responsive permeation performances of the composite membranes are satisfactorily reversible and reproducible. The membrane fabrication strategy in this work provides valuable guidance for further development of dual stimuli-responsive membranes or even multi stimuli-responsive membranes.

Vascular dementia (VaD) is the second most common type of dementia worldwide. Although there are five FDA-approved drugs for the treatment of Alzheimer’s disease (AD), none of them have been applied to treat VaD. Adalimumab is a TNF-α inhibitor that is used for the treatment of autoimmune diseases such as rheumatoid arthritis. In a recent retrospective case-control study, the application of adalimumab for rheumatoid or psoriasis was shown to decrease the risk of AD. However, whether adalimumab can be used for the treatment of VaD is not clear. In this study, we used 2VO surgery to generate a VaD rat model and treated the rats with adalimumab or vehicle. We demonstrated that VaD rats treated with adalimumab exhibited significant improvements in memory. In addition, adalimumab treatment significantly alleviated neuronal loss in the hippocampi of VaD rats. Moreover, adalimumab significantly reduced microglial activation and reversed M1/M2 polarization in VaD rats. Furthermore, adalimumab treatment suppressed the activity of NF-κB, an important neuroinflammatory transcription factor. Finally, adalimumab displayed a protective role against oxidative stress in VaD rats. Our results indicate that adalimumab may be applied for the treatment of human patients with VaD.

No abstract